Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Elizabeth E Tolley, Sahar Z Zangeneh, Gordon Chau, Joe Eron, Beatriz Grinsztejn, Hilton Humphries, Albert Liu, Marc Siegel, Maseko Bertha, Ravindre Panchia, Sue Li, Leslie Cottle, Alex Rinehart, David Margolis, Andrea Jennings, Marybeth McCauley, Raphael J Landovitz, Elizabeth E Tolley, Sahar Z Zangeneh, Gordon Chau, Joe Eron, Beatriz Grinsztejn, Hilton Humphries, Albert Liu, Marc Siegel, Maseko Bertha, Ravindre Panchia, Sue Li, Leslie Cottle, Alex Rinehart, David Margolis, Andrea Jennings, Marybeth McCauley, Raphael J Landovitz

Abstract

Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.

Keywords: Acceptability; Clinical trial; Females; HIV prevention; Injectable; Males; PrEP.

Figures

Fig. 1
Fig. 1
Acceptability of product attributes and physical experiences at week 6, by region and cohort 1
Fig. 2
Fig. 2
Acceptability of product attributes and physical experiences at week 6, by region and cohort 2

References

    1. World Health Organization HIV/AIDS. 2018;19:2018.
    1. UNAIDS . UNAIDS Data 2019. Switzerland: UNAIDS; 2019.
    1. UN Women. Facts and figures: HIV and AIDS. UN Women; 2018.
    1. Centers for Disease Control and Prevention . Estimated HIV incidence and prevalence in the United States, 2010–2016. Atlanta: CDC; 2019.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524.
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599. doi: 10.1056/NEJMoa1011205.
    1. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422. doi: 10.1056/NEJMoa1202614.
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518. doi: 10.1056/NEJMoa1402269.
    1. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4. doi: 10.1126/scitranslmed.3003174.
    1. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983. doi: 10.1097/QAD.0000000000001145.
    1. Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66(5):530–537. doi: 10.1097/QAI.0000000000000216.
    1. Sidebottom D, Ekstrom AM, Stromdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV: how can we improve uptake and adherence? BMC Infect Dis. 2018;18(1):581. doi: 10.1186/s12879-018-3463-4.
    1. Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity: United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147–1150. doi: 10.15585/mmwr.mm6741a3.
    1. Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N. PrEP for Africa: what we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS. 2016;11(1):80–86. doi: 10.1097/COH.0000000000000224.
    1. Venter WDF. Pre-exposure prophylaxis: the delivery challenge. Front Public Health. 2018;6:188. doi: 10.3389/fpubh.2018.00188.
    1. Eakle R, Venter F, Rees H. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: can it change the game? Retrovirology. 2018;15(1):29. doi: 10.1186/s12977-018-0408-3.
    1. Gutiérrez LB, Soriano V, Requena S, Arias A, Barreiro P, de Mendoza C. Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Rev Clin Pharmacol. 2018;11:507–517. doi: 10.1080/17512433.2018.1453805.
    1. Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016;11(1):122–128. doi: 10.1097/COH.0000000000000219.
    1. Bekker L-G, Li S, Tolley E, et al. HPTN 076: TMC278 LA Safe, Tolerable and Acceptable for HIV Pre-Exposure Prophylaxis. Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13–16, 2017; Seattle, Washington: CROI Foundation/IAS-USA; 2017.
    1. Tolley EE, Li S, Zanganeh SZ, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076) J Int AIDS Soc. 2019;22:e25408. doi: 10.1002/jia2.25408.
    1. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e340. doi: 10.1016/S2352-3018(17)30068-1.
    1. Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690. doi: 10.1371/journal.pmed.1002690.
    1. Meyers K, Rodriguez K, Brill AL, et al. Lessons for patient education around long-acting injectable PrEP: findings from a mixed-method study of phase II trial participants. AIDS Behav. 2018;22(4):1209–1216. doi: 10.1007/s10461-017-1871-x.
    1. Kerrigan D, Mantsios A, Grant R, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as PrEP in the context of a phase II trial in the United States. AIDS Behav. 2018;22(11):3540–3549. doi: 10.1007/s10461-017-2017-x.
    1. Pepe MS, Anderson GL. A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Commun Stat. 1994;23(4):939–951. doi: 10.1080/03610919408813210.
    1. Hosek SG, Rudy B, Landovitz R, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–29. doi: 10.1097/QAI.0000000000001179.
    1. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–e519. doi: 10.1016/S2352-3018(15)00206-4.
    1. Hodder SL, Justman J, Haley DF, et al. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S69–S73. doi: 10.1097/QAI.0b013e3181fbbdf9.
    1. Corneli A, Wang M, Agot K, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555–563. doi: 10.1097/QAI.0000000000000362.
    1. MacQueen KM, Dlamini S, Perry B, et al. Social context of adherence in an open-label 1% tenofovir gel trial: gender dynamics and disclosure in KwaZulu-Natal. South Africa. AIDS Behav. 2016;20:2682–2691. doi: 10.1007/s10461-016-1339-4.
    1. Roberts ST, Haberer J, Celum C, et al. Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: a prospective cohort study. J Acquir Immune Defic Syndr. 2016;73:313–322. doi: 10.1097/QAI.0000000000001093.
    1. van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118. doi: 10.1371/journal.pone.0089118.
    1. Tsui AO, Brown W, Li Q. Contraceptive practice in sub-Saharan Africa. Popul Dev Rev. 2017;43(Suppl 1):166–191. doi: 10.1111/padr.12051.
    1. Delany-Moretlwe S, Mullick S, Eakle R, Rees H. Planning for HIV preexposure prophylaxis introduction: lessons learned from contraception. Curr Opin HIV AIDS. 2016;11(1):87–93. doi: 10.1097/COH.0000000000000221.
    1. Aaron E, Blum C, Seidman D, et al. Optimizing delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDS. 2018;32(1):16–23. doi: 10.1089/apc.2017.0201.
    1. Calabrese SK, Krakower DS, Mayer KH. Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities. Am J Public Health. 2017;107(12):1883–1889. doi: 10.2105/AJPH.2017.304061.
    1. Calabrese SK, Magnus M, Mayer KH, et al. “Support your client at the space that they’re in”: HIV pre-exposure prophylaxis (PrEP) prescribers’ perspectives on PrEP-related risk compensation. AIDS Patient Care STDS. 2017;31(4):196–204. doi: 10.1089/apc.2017.0002.
    1. Lambert CC, Marrazzo J, Amico KR, Mugavero MJ. PrEParing women to prevent HIV: an integrated theoretical framework to PrEP black women in the United States. J Assoc Nurses AIDS Care. 2018;29(6):835–848. doi: 10.1016/j.jana.2018.03.005.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться